Edition:
United Kingdom

Takeda Pharmaceutical Co Ltd (4502.T)

4502.T on Tokyo Stock Exchange

3,540JPY
16 Aug 2019
Change (% chg)

¥-75 (-2.07%)
Prev Close
¥3,615
Open
¥3,556
Day's High
¥3,559
Day's Low
¥3,531
Volume
5,329,800
Avg. Vol
5,377,424
52-wk High
¥4,943
52-wk Low
¥3,498

Select another date:

Wed, Jul 17 2019

Photo

Takeda kicks off sale of Western European drugs - sources

FRANKFURT/LONDON Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters.

Takeda kicks off sale of Western European drugs: sources

FRANKFURT/LONDON Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters.

Takeda kicks off sale of Western European drugs - sources

FRANKFURT/LONDON, July 17 Japan's Takeda Pharmaceutical Co has reached out to prospective bidders for a portfolio of drugs for sale in western Europe as it seeks to trim its debt following the $59 billion purchase of Shire, sources close to the matter told Reuters.

Olympics - Japan's Yamashita appointed chief as Takeda resigns in graft probe

TOKYO The Japanese Olympic Committee (JOC) picked former Olympic judo champion Yasuhiro Yamashita as its new chief after the resignation of Tsunekazu Takeda, who is being investigated for suspected corruption related to the Tokyo 2020 bid.

Olympics: Japan's Yamashita appointed chief as Takeda resigns in graft probe

TOKYO, June 27 The Japanese Olympic Committee (JOC) picked former Olympic judo champion Yasuhiro Yamashita as its new chief after the resignation of Tsunekazu Takeda, who is being investigated for suspected corruption related to the Tokyo 2020 bid.

Takeda scraps late-stage amyloidosis study

Takeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a late-stage study testing its experimental treatment for amyloidosis, as it did not meet the first of two main goals.

Takeda scraps late-stage amyloidosis study

June 5 Takeda Pharmaceutical Co Ltd said on Wednesday it would discontinue a late-stage study testing its experimental treatment for amyloidosis, as it did not meet the first of two main goals.

Japan's Takeda expects binding offers for Latam business by end of May: sources

SAO PAULO Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources with knowledge of the matter said.

Japan's Takeda expects binding offers for Latam business by end of May -sources

SAO PAULO, May 16 Japan's Takeda Pharmaceutical Co expects to receive binding offers for its Latin American business by the end of May, three sources with knowledge of the matter said.

Japan's Takeda forecasts surprise annual loss on Shire-related costs

TOKYO Takeda Pharmaceutical Co forecast an unexpected operating loss for the current year due to costs associated with the $59 billion purchase of Shire Plc, providing the first set of financial results of the combined firm.

Select another date: